DOCSLIB.ORG

Fluid and Hyponatremia Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fluid and Hyponatremia Management Fluid and Hyponatremia Management By Craig B. Whitman, Pharm.D., BCPS, BCCCP Reviewed by Serena A. Harris, Pharm.D., BCPS, BCCCP; Ohoud A. Aljuhani, Pharm.D., BCCCP; and Abigail D. Antigua, Pharm.D., BCCCP LEARNING OBJECTIVES 1. Evaluate intravascular volume status and administer intravenous fluids (IVFs) to a critically ill patient. 2. Develop a plan to administer the appropriate IVF choice in a critically ill patient according to evidence from the literature. 3. Justify the use of peripheral administration of hypertonic saline and vasopressin antagonists to correct hyponatremia in a critically ill patient. 4. Demonstrate the role of desmopressin in preventing sodium overcorrection when treating hyponatremia. INTRAVENOUS FLUID THERAPY ABBREVIATIONS IN THIS CHAPTER AKI Acute kidney injury Introduction IVC Inferior vena cava Intravenous fluid (IVF) therapy has been used in clinical medicine IVF Intravenous fluid since the 1830s during the European cholera epidemic (Severs 2015). LOS Length of stay Many indications exist for IVF therapy in the critically ill population. RRT Renal replacement therapy Intravascular volume replacement is the most common reason for SIADH Syndrome of inappropriate using large volumes of IVF in the ICU, with sepsis, trauma, burn, antidiuretic hormone and perioperative volume loss requiring replacement. Hypovolemia TBI Traumatic brain injury occurs with reduction of extracellular volume and requires replace- ment with IVF. Electrolyte repletion, management of acidosis, and Table of other common abbreviations. prevention and management of drug-induced toxicities are other examples of common indications for IVF (Severs 2015). Many IVFs have been developed to optimize composition and administration in patients requiring treatment. These solutions are classified as crys- talloids and colloids. Crystalloid solutions contain small solutes with various amounts of water. The prototypical crystalloid solution is 0.9% sodium chloride (normal saline), with lactated Ringer solution and other various “balanced crystalloid” solutions available for IVF therapy. Intravascular volume expansion from normal saline is main- tained for up to 6 hours, with close to one-half of the infusate located in the interstitium (Severs 2015). Colloid solutions contain large mole- cules that more effectively maintain intravascular volume by exerting an oncotic pressure. Available colloids include iso-oncotic (4%–5%) and hyperoncotic (20%–25%) albumin solutions, semisynthetic col- loids like hydroxyethyl starch, dextrans, gelatins, and blood products. Despite the longstanding use of available IVFs, considerable debate exists regarding the optimal fluid choice, dose, and method of administration in the critically ill population. This chapter aims to discuss recent advances in knowledge of IVF therapy and provide insight into optimal use of various fluid choices in this population. CCSAP 2018 Book 3 • Fluids and Nutrition/GI and Liver Disorders 7 Fluid and Hyponatremia Management Assessment of Volume Status or large body habitus. In general, static measurements of in the Critically Ill Patient intravascular blood volume (e.g., central venous or pulmo- Assessing intravascular volume status and fluid responsive- nary artery occlusion pressure) should be avoided as the ness in critically ill patients is one of the more challenging sole assessment method (Rhodes 2017; Kalantari 2013). To a s p e c t s o f m a n a g i n g I V F t h e r a p y i n t h i s p o p u l a t i o n . A p p r o p r i a t e optimize therapy, intravascular volume should continually be assessment is important because it may mitigate a positive assessed and reassessed in patients who receive IVF. fluid balance, which may be associated with increased mor- tality (Malbrain 2014). A variety of methods including physical IVF Administration in Critically Ill Patients examination, chest radiography, laboratory values, and inva- Fluid may be administered in a variety of ways in critically ill sive monitoring can be used to assess volume status. There patients. The 12th Acute Dialysis Quality Initiative Conference is no universally accepted method to assess intravascular workgroup has proposed definitions pertinent to fluid adminis- volume in critically ill patients. Physical examination findings tration (Hoste 2014). Fluid bolus is a rapid infusion to correct should be used during the initial evaluation of intravascular intravascular volume status in shock states that consists of at volume status and combined with dynamic measurements least 500 mL over a maximum of 15 minutes. A fluid challenge is of blood volume. The Surviving Sepsis Campaign guide- a rapid infusion to correct hemodynamic instability, administer- lines recommend using dynamic variables to assess fluid ing 100–200 mL over 5–10 minutes followed by reassessment responsiveness, including passive leg raises, pulse pres- (Hoste 2014). The Surviving Sepsis Campaign recommends sure variation, and stroke volume variation (Rhodes 2017). 30 mL/kg as the initial fluid challenge in patients with sep- Esophageal Doppler monitoring and ultrasound measure- sis (Rhodes 2017). Fluid infusion is the continuous delivery of ment of the inferior vena cava (IVC) can also be considered IVF to maintain homeostasis, replace losses, or prevent organ if the equipment is available and the operator has expertise injury. Maintenance infusion is administration to provide flu- in its use. Esophageal Doppler monitoring may be limited ids for patients who cannot maintain their needs by the oral or because it requires the patient to be sedated (Kalantari 2013). enteral route. For individuals without ongoing losses, a maxi- The accuracy of IVC ultrasonography may be affected by mum rate of 1–2 mL/kg/hour is recommended (Hoste 2014). elevated intra-abdominal pressure (e.g., post-laparotomy) Four distinct phases of fluid therapy in resuscitation have been proposed: rescue, optimization, stabilization, and de-escalation (Rewa 2015). The rescue phase occurs with hemodynamic instability and associated impaired organ perfusion, resulting BASELINE KNOWLEDGE STATEMENTS in life-threatening shock. Intravenous fluids are administered Readers of this chapter are presumed to be familiar using boluses in the rescue phase. Optimization is when the with the following: patient is no longer at imminent risk of life-threatening shock • Understanding of intravascular fluid composition, but requires fluid therapy to optimize cardiac function, sus- mechanism of action, and toxicities tain tissue perfusion, mitigate organ dysfunction, and achieve • Understanding of sodium and water physiology physiologic end points. Methods of fluid administration in this and homeostasis phase vary between bolus, fluid challenge, and continuous • General knowledge of pathophysiology and infusion. During the stabilization phase, the goals of fluid ther- differentiation of sodium disorders apy are to provide ongoing organ support, prevent worsening • Knowledge of modes of renal replacement therapy organ dysfunction, and avoid further complications. The need used in critically ill patients for fluid during this phase is directed toward maintaining intra- Knowledge of standard treatment approaches for • vascular volume homeostasis and replacing ongoing losses. sodium abnormalities Fluid challenge and continuous infusion are the methods of IVF Table of common laboratory reference values. administration during stabilization. The de-escalation phase occurs with mobilization and removal of accumulated fluid. ADDITIONAL READINGS With recovery and decreasing illness severity, a negative fluid balance is typically targeted and may be achieved by sponta- The following free resources have additional back- neous or active diuresis of the patient (Rewa 2015). ground information on this topic: • Surviving Sepsis Campaign: international guide- lines for management of sepsis and septic shock: CONTROVERSIES IN FLUID 2016. Crit Care Med 2017;45:486-552. RESUSCITATION • Verbalis JG, Goldsmith SR, Greenberg A, et al. Crystalloids vs. Colloids Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Theoretical advantages exist for using one type of IVF versus Am J Med 2013;126:s1-s42. another. Colloids may more effectively maintain intravascu- lar volume status, leading to potentially less total volume CCSAP 2018 Book 3 • Fluids and Nutrition/GI and Liver Disorders 8 Fluid and Hyponatremia Management administered, which may reduce significant edema (Rewa the first ICU week: 2 L (interquartile range [IQR] 1–3.5) com- 2015). However, albumin costs as much as 30 times more pared with 3 L (IQR 0.5–3.2) (p<0.001). Despite equivalent than normal saline or lactated Ringer solution (Severs 2015). outcomes, this study had many significant limitations. About Meta-analyses of small studies evaluating the difference 25% of subjects received open-label fluid administration. The between crystalloid and colloid solutions have had mixed study duration extended over 9 years, which may also reflect results, leading to questionable effects of colloids on mortal- inconsistencies in practice over that time and changes in ity (Finfer 2004). guideline recommendations. Finally, the study allowed a vari- The Saline versus Albumin Fluid Evaluation (SAFE) study ety of fluids to be chosen at the clinician’s discretion, making was the first large, multicenter, double-blind, controlled trial it extremely difficult to ascertain any difference between the to evaluate differences in clinical outcomes between
Load more

Recommended publications
  • Hyponatremia and Hypernatremia MICHAEL M
    This is a corrected version of the article that appeared in print. Diagnosis and Management of Sodium Disorders: Hyponatremia and Hypernatremia MICHAEL M. BRAUN, DO, Madigan Army Medical Center, Tacoma, Washington CRAIG H. BARSTOW, MD, Womack Army Medical Center, Fort Bragg, North Carolina NATASHA J. PYZOCHA, DO, Madigan Army Medical Center, Tacoma, Washington Hyponatremia and hypernatremia are common findings in the inpatient and outpatient settings. Sodium disorders are associated with an increased risk of morbidity and mortality. Plasma osmolality plays a critical role in the patho- physiology and treatment of sodium disorders. Hyponatremia and hypernatremia are classified based on volume status (hypovolemia, euvolemia, and hypervolemia). Sodium disorders are diagnosed by findings from the history, physical examination, laboratory studies, and evaluation of volume status. Treatment is based on symptoms and underlying causes. In general, hyponatremia is treated with fluid restriction (in the setting of euvolemia), isotonic saline (in hypovolemia), and diuresis (in hypervolemia). A combination of these therapies may be needed based on the presentation. Hypertonic saline is used to treat severe symptomatic hyponatremia. Medications such as vaptans may have a role in the treatment of euvolemic and hypervolemic hyponatremia. The treatment of hypernatremia involves correcting the underlying cause and correcting the free water deficit. Am( Fam Physician. 2015;91(5):299-307. Copy- right © 2015 American Academy of Family Physicians.) More online yponatremia is a common elec- a worse prognosis in patients with liver cir- at http://www. trolyte disorder defined as a rhosis, pulmonary hypertension, myocardial aafp.org/afp. serum sodium level of less than infarction, chronic kidney disease, hip frac- CME This clinical content 135 mEq per L.1-3 A Dutch sys- tures, and pulmonary embolism.1,8-10 conforms to AAFP criteria Htematic review of 53 studies showed that the for continuing medical Etiology and Pathophysiology education (CME).
    [Show full text]
  • DDAVP Nasal Spray Is Provided As an Aqueous Solution for Intranasal Use
    DDAVP® Nasal Spray (desmopressin acetate) Rx only DESCRIPTION DDAVP® Nasal Spray (desmopressin acetate) is a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation. It is chemically defined as follows: Mol. wt. 1183.34 Empirical formula: C46H64N14O12S2•C2H4O2•3H2O 1-(3-mercaptopropionic acid)-8-D-arginine vasopressin monoacetate (salt) trihydrate. DDAVP Nasal Spray is provided as an aqueous solution for intranasal use. Each mL contains: Desmopressin acetate 0.1 mg Sodium Chloride 7.5 mg Citric acid monohydrate 1.7 mg Disodium phosphate dihydrate 3.0 mg Benzalkonium chloride solution (50%) 0.2 mg The DDAVP Nasal Spray compression pump delivers 0.1 mL (10 mcg) of DDAVP (desmopressin acetate) per spray. CLINICAL PHARMACOLOGY DDAVP contains as active substance desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin. One mL (0.1 mg) of intranasal DDAVP has an antidiuretic activity of about 400 IU; 10 mcg of desmopressin acetate is equivalent to 40 IU. 1. The biphasic half-lives for intranasal DDAVP were 7.8 and 75.5 minutes for the fast and slow phases, compared with 2.5 and 14.5 minutes for lysine vasopressin, another form of the hormone used in this condition. As a result, intranasal DDAVP provides a prompt onset of antidiuretic action with a long duration after each administration. 1 2. The change in structure of arginine vasopressin to DDAVP has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.
    [Show full text]
  • Versus High-Chloride-Containing Hypertonic Solution for the Treatment
    Sadan et al. Journal of Intensive Care (2020) 8:32 https://doi.org/10.1186/s40560-020-00449-0 RESEARCH Open Access Low-chloride- versus high-chloride- containing hypertonic solution for the treatment of subarachnoid hemorrhage– related complications: The ACETatE (A low ChloriE hyperTonic solution for brain Edema) randomized trial Ofer Sadan1*, Kai Singbartl2, Jacqueline Kraft1, Joao McONeil Plancher1, Alexander C. M. Greven3, Prem Kandiah1, Cederic Pimentel1, C. L. Hall1, Alexander Papangelou4, William H. Asbury5, John J. Hanfelt6 and Owen Samuels1 Abstract Background: Recent reports have demonstrated that among patients with subarachnoid hemorrhage (SAH) treated with hypertonic NaCl, resultant hyperchloremia has been associated with the development of acute kidney injury (AKI). We report a trial comparing the effect of two hypertonic solutions with different chloride contents on the resultant serum chloride concentrations in SAH patients, with a primary outcome aimed at limiting chloride elevation. Methods: A low ChloridE hyperTonic solution for brain Edema (ACETatE) trial is a single-center, double-blinded, double-dummy, randomized pilot trial comparing bolus infusions of 23.4% NaCl and 16.4% NaCl/Na-acetate for the treatment of cerebral edema in patients with SAH. Randomization occurred when patients developed hyperchloremia (serum Cl− ≥ 109 mmol/L) and required hyperosmolar treatment. Results: We enrolled 59 patients, of which 32 developed hyperchloremia and required hyperosmolar treatment. 15 patients were randomized to the 23.4% NaCl group, and 17 patients were randomized to the 16.4% NaCl/Na- acetate group. Although serum chloride levels increased similarly in both groups, the NaCl/Acetate group showed a significantly lower Cl− load at the end of the study period (978mEq vs.
    [Show full text]
  • Clinical Physiology Aspects of Chloremia in Fluid Therapy: a Systematic Review David Astapenko1,2* , Pavel Navratil2,3, Jiri Pouska4,5 and Vladimir Cerny1,2,6,7,8,9
    Astapenko et al. Perioperative Medicine (2020) 9:40 https://doi.org/10.1186/s13741-020-00171-3 REVIEW Open Access Clinical physiology aspects of chloremia in fluid therapy: a systematic review David Astapenko1,2* , Pavel Navratil2,3, Jiri Pouska4,5 and Vladimir Cerny1,2,6,7,8,9 Abstract Background: This systematic review discusses a clinical physiology aspect of chloride in fluid therapy. Crystalloid solutions are one of the most widely used remedies. While generally used in medicine for almost 190 years, studies focused largely on their safety have only been published since the new millennium. The most widely used solution, normal saline, is most often referred to in this context. Its excessive administration results in hyperchloremic metabolic acidosis with other consequences, including higher mortality rates. Methods: Original papers and review articles eligible for developing the present paper were identified by searching online in the electronic MEDLINE database. The keywords searched for included hyperchloremia, hypochloremia, and compound words containing the word “chloride,” infusion therapy, metabolic acidosis, renal failure, and review. Results: A total of 21,758 papers published before 31 May 2020 were identified; of this number, 630 duplicates were removed from the list. Upon excluding articles based on their title or abstract, 1850 papers were screened, of which 63 full-text articles were assessed. Conclusions: According to the latest medical concepts, dyschloremia (both hyperchloremia and hypochloremia) represents a factor indisputably having a negative effect on selected variables of clinical outcome. As infusion therapy can significantly impact chloride homeostasis of the body, the choice of infusion solutions should always take into account the potentially adverse impact of chloride content on chloremia and organ function.
    [Show full text]
  • Spray Desmopressin Acetate Nasal Spray 10 Μg/Spray
    PRODUCT MONOGRAPH Pr DDAVP® Spray Desmopressin Acetate Nasal Spray 10 µg/spray Pr DDAVP® Rhinyle Desmopressin Acetate Nasal Solution 0.1 mg/mL Antidiuretic Ferring Inc. Date of Revision: 200 Yorkland Blvd, Suite 800 June 19, 2008 North York, Ontario M2J 5C1 Submission Control No: 119073 DDAVP® Spray and Rhinyle Page 1 of 23 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION.........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE..............................................................................3 WARNINGS AND PRECAUTIONS..................................................................................4 ADVERSE REACTIONS....................................................................................................6 DRUG INTERACTIONS ....................................................................................................7 DOSAGE AND ADMINISTRATION................................................................................7 OVERDOSAGE ..................................................................................................................9 ACTION AND CLINICAL PHARMACOLOGY ..............................................................9 STORAGE AND STABILITY..........................................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................11 PART II: SCIENTIFIC INFORMATION
    [Show full text]
  • Renal Tubular Acidosis in Children: State of the Art, Diagnosis and Treatment
    www.medigraphic.org.mx Bol Med Hosp Infant Mex 2013;70(3):178-193 REVIEW ARTICLE Renal tubular acidosis in children: state of the art, diagnosis and treatment Ricardo Muñoz-Arizpe,1 Laura Escobar,2 Mara Medeiros3 ABSTRACT Overdiagnosis of renal tubular acidosis (RTA) has been recently detected in Mexican children, perhaps due to diagnostic errors as well as due to a lack of knowledge regarding the pathophysiology and molecular biochemistry involved in this illness. The objective of the present study is to facilitate the knowledge and diagnosis of RTA, a clinical condition infrequently seen worldwide. RTA is an alteration of the acid-base equilibrium due to a bicarbonate wasting in the proximal renal tubules [proximal RTA, (pRTA) or type 2 RTA] or due to a distal nephron hy- drogen ion excretion defect [distal RTA (dRTA) or type 1 RTA]. Hyperkalemic, or type 4 RTA, is due to alterations in aldosterone metabolism. RTA may be primary, secondary, acquired or hereditary and frequently presents secondary to an array of systemic diseases, usually accom- panied by multiple renal tubular defects. The main defect occurs in the transmembrane transporters such as carbonic anhydrase (CA I and + - - + - II), H -ATPase, HCO3 /Cl (AE1) exchanger and Na /HCO3 (NBCe1) cotransporter. Diagnosis should include the presence of hyperchloremic metabolic acidosis with normal serum anion gap (done in an arterial or arterialized blood sample), lack of appetite, polyuria, thirst, growth failure, and rickets; nephrocalcinosis and renal stones (in dRTA); abnormal urine anion gap and abnormal urine/serum pCO2 gradient. Diagnosis of a primary systemic disease must be made in cases of secondary RTA.
    [Show full text]
  • Oxytocin Regulates the Expression of Aquaporin 5 in the Latepregnant Rat
    RESEARCH ARTICLE Molecular Reproduction & Development 81:524–530 (2014) Oxytocin Regulates the Expression of Aquaporin 5 in the Late-Pregnant Rat Uterus ESZTER DUCZA,* ADRIENN B. SERES, JUDIT HAJAGOS-TOTH, GEORGE FALKAY, AND ROBERT GASPAR Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary SUMMARY Aquaporins (AQPs) are integral membrane channels responsible for the transport of water across a cell membrane. Based on reports that AQPs are present and accumulate in the female reproductive tract late in pregnancy, our aim was to study the expression of AQP isoforms (AQP1, 2, 3, 5, 8, and 9) at the end of pregnancy in rat in order to determine if they play a role in parturition. Reverse-transcriptase PCR revealed that specific Aqp mRNAs were detectable in the myometrium of non- pregnant and late-pregnancy (Days 18, 20, 21, and 22 of pregnancy) rat uteri. The expression of Aqp5 mRNA and protein were most pronounced on Days 18À21, and were dramatically decreased on Day 22 of pregnancy. In contrast, a significant increase was found in the level of Aqp5 transcript in whole-blood samples ÃCorresponding author: on the last day of pregnancy.The effect of oxytocin on myometrial Aqp5 expression in Department of Pharmacodynamics an organ bath was also investigated. The level of Aqp5 mRNA significantly decreased and Biopharmacy À8 University of Szeged, H-6720 5 min after oxytocin (10 M) administration, similarly to its profile on the day of Eotv€ os€ u. 6, Szeged 6270 delivery; this effect was sensitive to the oxytocin antagonist atosiban. The vasopres- Hungary.
    [Show full text]
  • Management and Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
    REVIEW Management and treatment of lithium- induced nephrogenic diabetes insipidus Christopher K Finch†, Lithium carbonate is a well documented cause of nephrogenic diabetes insipidus, with as Tyson WA Brooks, many as 10 to 15% of patients taking lithium developing this condition. Clinicians have Peggy Yam & Kristi W Kelley been well aware of lithium toxicity for many years; however, the treatment of this drug- induced condition has generally been remedied by discontinuation of the medication or a †Author for correspondence Methodist University reduction in dose. For those patients unresponsive to traditional treatment measures, Hospital, Department several pharmacotherapeutic regimens have been documented as being effective for the of Pharmacy, University of management of lithium-induced diabetes insipidus including hydrochlorothiazide, Tennessee, College of Pharmacy, 1265 Union Ave., amiloride, indomethacin, desmopressin and correction of serum lithium levels. Memphis, TN 38104, USA Tel.: +1 901 516 2954 Fax: +1 901 516 8178 [email protected] Lithium carbonate is well known for its wide use associated with a mutation(s) of vasopressin in bipolar disorders due to its mood stabilizing receptors. Acquired causes are tubulointerstitial properties. It is also employed in aggression dis- disease (e.g., sickle cell disease, amyloidosis, orders, post-traumatic stress disorders, conduct obstructive uropathy), electrolyte disorders (e.g., disorders and even as adjunctive therapy in hypokalemia and hypercalcemia), pregnancy, or depression. Lithium has many well documented conditions induced by a drug (e.g., lithium, adverse effects as well as a relatively narrow ther- demeclocycline, amphotericin B and apeutic range of 0.4 to 0.8 mmol/l. Clinically vincristine) [3,4]. Lithium is the most common significant adverse effects include polyuria, mus- cause of drug-induced nephrogenic DI [5].
    [Show full text]
  • Vasopressin V2 Is a Promiscuous G Protein-Coupled Receptor That Is Biased by Its Peptide Ligands
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.28.427950; this version posted January 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Vasopressin V2 is a promiscuous G protein-coupled receptor that is biased by its peptide ligands. Franziska M. Heydenreich1,2,3*, Bianca Plouffe2,4, Aurélien Rizk1, Dalibor Milić1,5, Joris Zhou2, Billy Breton2, Christian Le Gouill2, Asuka Inoue6, Michel Bouvier2,* and Dmitry B. Veprintsev1,7,8,* 1Laboratory of Biomolecular Research, Paul Scherrer Institute, 5232 Villigen PSI, Switzerland and Department of Biology, ETH Zürich, 8093 Zürich, Switzerland 2Department of Biochemistry and Molecular medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada 3Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305, USA 4The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, United Kingdom 5Department of Structural and Computational Biology, Max Perutz Labs, University of Vienna, Campus-Vienna-Biocenter 5, 1030 Vienna, Austria 6Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan. 7Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, UK. 8Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, NG7 2UH, UK. *Correspondence should be addressed to: [email protected], [email protected], [email protected].
    [Show full text]
  • Hyperchloremia – Why and How
    Document downloaded from http://www.elsevier.es, day 23/05/2017. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. n e f r o l o g i a 2 0 1 6;3 6(4):347–353 Revista de la Sociedad Española de Nefrología www.revistanefrologia.com Brief review Hyperchloremia – Why and how Glenn T. Nagami Nephrology Section, Department of Medicine, VA Greater Los Angeles Healthcare System and David Geffen School of Medicine at UCLA, United States a r t i c l e i n f o a b s t r a c t Article history: Hyperchloremia is a common electrolyte disorder that is associated with a diverse group of Received 5 April 2016 clinical conditions. The kidney plays an important role in the regulation of chloride concen- Accepted 11 April 2016 tration through a variety of transporters that are present along the nephron. Nevertheless, Available online 3 June 2016 hyperchloremia can occur when water losses exceed sodium and chloride losses, when the capacity to handle excessive chloride is overwhelmed, or when the serum bicarbonate is low Keywords: with a concomitant rise in chloride as occurs with a normal anion gap metabolic acidosis Hyperchloremia or respiratory alkalosis. The varied nature of the underlying causes of the hyperchloremia Electrolyte disorder will, to a large extent, determine how to treat this electrolyte disturbance. Serum bicarbonate Published by Elsevier Espana,˜ S.L.U. on behalf of Sociedad Espanola˜ de Nefrologıa.´ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
    [Show full text]
  • Electrolyte and Acid-Base Disorders Triggered by Aminoglycoside Or Colistin Therapy: a Systematic Review
    antibiotics Review Electrolyte and Acid-Base Disorders Triggered by Aminoglycoside or Colistin Therapy: A Systematic Review Martin Scoglio 1,* , Gabriel Bronz 1, Pietro O. Rinoldi 1,2, Pietro B. Faré 3,Céline Betti 1,2, Mario G. Bianchetti 1, Giacomo D. Simonetti 1,2, Viola Gennaro 1, Samuele Renzi 4, Sebastiano A. G. Lava 5 and Gregorio P. Milani 2,6,7 1 Faculty of Biomedicine, Università della Svizzera Italiana, 6900 Lugano, Switzerland; [email protected] (G.B.); [email protected] (P.O.R.); [email protected] (C.B.); [email protected] (M.G.B.); [email protected] (G.D.S.); [email protected] (V.G.) 2 Department of Pediatrics, Pediatric Institute of Southern Switzerland, Ospedale San Giovanni, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland; [email protected] 3 Department of Internal Medicine, Ospedale La Carità, Ente Ospedaliero Cantonale, 6600 Locarno, Switzerland; [email protected] 4 Division of Hematology and Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada; [email protected] 5 Pediatric Cardiology Unit, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois, and University of Lausanne, 1011 Lausanne, Switzerland; [email protected] 6 Pediatric Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy 7 Department of Clinical Sciences and Community Health, Università degli Studi di Milano, 20122 Milan, Italy * Correspondence: [email protected] Citation: Scoglio, M.; Bronz, G.; Abstract: Aminoglycoside or colistin therapy may alter the renal tubular function without decreasing Rinoldi, P.O.; Faré, P.B.; Betti, C.; the glomerular filtration rate. This association has never been extensively investigated.
    [Show full text]
  • Is There a Relationship Between COVID-19 and Hyponatremia?
    medicina Review Is There a Relationship between COVID-19 and Hyponatremia? Gina Gheorghe 1,2,†, Madalina Ilie 1,2, Simona Bungau 3,† , Anca Mihaela Pantea Stoian 4 , Nicolae Bacalbasa 5 and Camelia Cristina Diaconu 6,7,* 1 Department of Gastroenterology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania; [email protected] (G.G.); [email protected] (M.I.) 2 Department of Gastroenterology, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania 3 Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania; [email protected] 4 Department of Diabetes, Nutrition and Metabolic Diseases, “Carol Davila” University of Medicine and Pharmacy, 020475 Bucharest, Romania; [email protected] 5 Department of Visceral Surgery, Center of Excellence in Translational Medicine, Fundeni Clinical Institute, 022328 Bucharest, Romania; [email protected] 6 Department of Internal Medicine, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania 7 Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, 105402 Bucharest, Romania * Correspondence: [email protected]; Tel.: +40-0726-377-300 † This author has equal contribution to the paper as the first author. Abstract: Nowadays, humanity faces one of the most serious health crises, the severe acute respi- ratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The severity of coronavirus disease 2019 (COVID-19) pandemic is related to the high rate of interhuman transmission of the virus, variability of clinical presentation, and the absence of specific therapeutic methods. COVID-19 can manifest with non-specific symptoms and signs, especially among the elderly. In some cases, the clinical manifestations of hyponatremia may be the first to appear.
    [Show full text]